Keywords
erythrocyte alloimmunization
extended phenotyping
transfusion safety
genotyping
How to Cite
Abstract
Introduction
Erythrocyte alloimmunization remains a profound and pervasive complication in the clinical management of sickle cell disease (SCD).
Purpose
This study evaluates the global pooled prevalence of red blood cell antibodies and structural minor blood group antigenic variations that compromise transfusion safety across international cohorts.
Methods
Following PRISMA guidelines, a systematic literature search was performed using PubMed and Google Scholar. Nine high-quality observational studies published between 2012 and 2025 were selected, aggregating data from 1,241 multi-transfused SCD patients across four continents. To account for baseline clinical and geographical diversity, raw proportions were normalized via logit transformation and synthesized using a random-effects model.
Results
The global pooled prevalence of erythrocyte alloimmunization among multi-transfused SCD patients was 17.45% (95% CI: [10.09, 26.67]). Extreme statistical heterogeneity was observed (I2 = 91.32%, Q = 92.146, p < 0.001), highlighting critical discrepancies between advanced proactive matching facilities (8.05%) and heavily pre-sensitized cohorts (68.42%). Phenotypic risk analysis revealed a 72.72% overall prevalence of the evolutionary null Duffy phenotype Fy(a-b-), a low KEL1 antigen prevalence of 3.32%, and an at-risk Kidd profile rate of 46.57%.
Conclusion
The high 17.45% alloimmunization rate reflects chronic antigenic exposure combined with systematic donor-recipient demographic mismatches. The evolutionary Fy(a-b-)} malaria-resistant profile acts as a major post-transfusion risk barrier when patients receive blood from dominant Caucasian donor pools. Transitioning from basic ABO-RhD compatibility to routine, extended serological phenotyping or molecular genotyping for minor systems (Rh subgroups, Kell, Duffy, Kidd, MNS) is a critical public health priority to eliminate delayed hemolytic transfusion reactions and optimize clinical care. Systematic Review Registration: PROSPERO CRD420261363920.
References
Al Breiki, A. S., Al Kindi, S., & Castilho, L. (2024). Red blood cell extended antigen typing in Omani patients with sickle cell disease to enhance daily transfusion practice. Immunohematology, 40(3), 93–99. https://doi.org/10.2478/immunohematology-2024-0014
Alkindi, S., AlMahrooqi, S., AlHinai, S., AlMarhoobi, A., Al-Hosni, S., Daar, S., Fawaz, N., & Pathare, A. (2017). Alloimmunization in patients with sickle cell disease and thalassemia: Experience of a single centre in Oman. Mediterranean Journal of Hematology and Infectious Diseases, 9(1), e2017013. https://doi.org/10.4084/MJHID.2017.013
Bernit, E., Jean, E., Marlot, B., Laget, L., Izard, C., Dettori, I., Beley, S., Gautier, I., Agouti, I., Frassati, C., Pedini, P., Picard, C., Paganini, J., Chiaroni, J., & Di Cristofaro, J. (2023). HLA-F and LILRB1 genetic polymorphisms associated with alloimmunization in sickle cell disease. International Journal of Molecular Sciences, 24(17), 13591. https://doi.org/10.3390/ijms241713591
Boateng, L. A., Campbell, A. D., Davenport, R. D., Osei-Akoto, A., Hugan, S., Asamoah, A., & Schonewille, H. (2019). Red blood cell alloimmunization and minor red blood cell antigen phenotypes in transfused Ghanaian patients with sickle cell disease. Transfusion, 59(6), 2016–2022. https://doi.org/10.1111/trf.15197
Chinedu, O., Hezekiah, I. A., Akinloye, O. B., Samuel, A., Ofakunrin, A. O., Ogbe, O. P., Amaechi, R., & Nnodu, O. E. (2025). The prevalence and pattern of alloimmunization in patients with sickle cell disease in Abuja, Nigeria. Transfusion and Apheresis Science, 64(3), 104107. https://doi.org/10.1016/j.transci.2025.104107
Chou, S. T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., Stowell, S. R., Thein, S. L., Westhoff, C. M., Wong, T. E., & Akl, E. A. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: Transfusion support. Blood Advances, 4(2), 327–355. https://doi.org/10.1182/bloodadvances.2019001143
Compernolle, V., Chou, S. T., Tanael, S., Savage, W., Howard, J., Josephson, C. D., Odame, I., Hogan, C., Denomme, G., Shehata, N., & International Collaboration for Transfusion Medicine Guidelines. (2018). Red blood cell specifications for patients with hemoglobinopathies: A systematic review and guideline. Transfusion, 58(6), 1555–1566. https://doi.org/10.1111/trf.14611
Conrath, S., Vantilcke, V., Parisot, M., Maire, F., Selles, P., & Elenga, N. (2021). Increased prevalence of alloimmunization in sickle cell disease? Should we restore blood donation in French Guiana? Frontiers in Medicine, 8, 681549. https://doi.org/10.3389/fmed.2021.681549
da Cunha Gomes, E. G., Machado, L. A. F., de Oliveira, L. C., & Neto, J. F. N. (2019). The erythrocyte alloimmunization in patients with sickle cell anemia: A systematic review. Transfusion Medicine, 29(3), 149–161. https://doi.org/10.1111/tme.12543
Dinardo, C. L., Oliveira, T. G. M., Kelly, S., Ashley-Koch, A., Telen, M., Schmidt, L. C., Castilho, S., Melo, K., Dezan, M. R., Wheeler, M. M., Johnsen, J. M., Nickerson, D. A., Jain, D., Custer, B., Pereira, A. C., Sabino, E. C., & NHLBI Recipient Epidemiology Donor Evaluation Study (REDS-III) International Component-Brazil. (2021). Diversity of variant alleles encoding Kidd, Duffy, and Kell antigens in individuals with sickle cell disease using whole genome sequencing data from the NHLBI TOPMed Program. Transfusion, 61(2), 603–616. https://doi.org/10.1111/trf.16204
Felimban, R., Alsharyufi, A., Aljehani, J., Sahlool, A., Aljabri, H., & Qadah, T. (2021). Prevalence of red blood cell alloimmunization among beta-thalassemia and sickle cell anemia patients: A study from Saudi Arabia. Clinical Laboratory, 67(10), 210212. https://doi.org/10.7754/Clin.Lab.2021.210212
Gehrie, E. A., Savani, B. N., & Booth, G. S. (2021). Risk factors for hemolytic transfusion reactions resulting from ABO and minor red cell antigen incompatibility: From mislabeled samples to stem cell transplant and sickle cell disease. Blood Reviews, 45, 100719. https://doi.org/10.1016/j.blre.2020.100719
Jeyamurugan, K., Jung, M.-K., Viswanathan, K., Kupferman, F., & Peichev, M. (2024). Role of Duffy-negative phenotype in pediatric sickle cell population. Clinical Pediatrics, 63(1), 122–125. https://doi.org/10.1177/00099228231166928
Karafin, M. S., & Howard, J. (2022). Genotyping and the future of transfusion in sickle cell disease. Hematology/Oncology Clinics of North America, 36(6), 1271–1284. https://doi.org/10.1016/j.hoc.2022.07.012
Leal, I., dos Santos, T. D., Gilli, S., & Castilho, L. (2023). Effects of prophylactic red blood cell (RBC) transfusion with extended antigen matching on alloimmunization in patients with sickle cell disease (SCD). Transfusion and Apheresis Science, 62(6), 103813. https://doi.org/10.1016/j.transci.2023.103813
Linder, G. E., & Chou, S. T. (2021). Red cell transfusion and alloimmunization in sickle cell disease. Haematologica, 106(7), 1805–1815. https://doi.org/10.3324/haematol.2020.270546
Martins, J. O., Pagani, F., Dezan, M. R., Oliveira, V. B., Conrado, M., Ziza, K. C., Gualandro, S. F. M., Langui, D. M., Bordin, J. O., Rocha, V., Mendrone-Júnior, A., & Dinardo, C. L. (2022). Impact of HLA-G +3142C>G on the development of antibodies to blood group systems other than the Rh and Kell among sensitized patients with sickle cell disease. Transfusion and Apheresis Science, 61(5), 103447. https://doi.org/10.1016/j.transci.2022.103447
Novelli, E. M., & Gladwin, M. T. (2016). Crises in sickle cell disease. Chest, 149(4), 1082–1093. https://doi.org/10.1016/j.chest.2015.12.016
Oladipupo, F., Stanek, J., Walden, J., Young, J., Rose, M. J., Nicol, K., Villella, A., & Creary, S. (2024). Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States. Pediatric Blood & Cancer, 71(6), e30945. https://doi.org/10.1002/pbc.30945
Özpolat, T., Chang, T. C., Wu, X., St. John, A. E., Konkle, B. A., Chen, J., & López, J. A. (2022). Phenotypic analysis of erythrocytes in sickle cell disease using imaging flow cytometry. Cytometry Part A, 101(5), 448–457. https://doi.org/10.1002/cyto.a.24536
Pincez, T., Lo, K. S., d'Alexandry d'Orengiani, A.-L. P. H., Garrett, M. E., Brugnara, C., Ashley-Koch, A. E., Telen, M. J., Galacteros, F., Joly, P., Bartolucci, P., & Lettre, G. (2022). Variation and impact of polygenic hematologic traits in monogenic sickle cell disease. Haematologica, 108(3), 870–881. https://doi.org/10.3324/haematol.2022.281180
Pirenne, F., Floch, A., & Diop, S. (2023). Alloimmunization against red blood cells in sickle cell disease: Transfusion challenges in high-income and low-income countries. The Lancet Haematology, 10(6), e468–e476. https://doi.org/10.1016/S2352-3026(23)00066-2
Regalado-Artamendi, I., Pérez-Corral, A. M., García-Morín, M., Cela, E., Beléndez, C., Bardón-Cancho, E. J., Pérez-Rus, G., Pérez-Sánchez, I., Pascual, C., Monsalvo, S., Falero, C., Díez-Martín, J. L., & Anguita, J. (2021). Complete RH and Kell matching related to low alloimmunization risk in sickle cell disease: Prevalence and risk factors of alloimmunization in a Spanish tertiary care national reference center. Blood Transfusion, 19(4), 292–299. https://doi.org/10.2450/2020.0096-20
Seck, M., Senghor, A. B., Loum, M., Touré, S. A., Faye, B. F., Diallo, B. B., Keita, M., Bousso, S. E., Guèye, S. M., Gadji, M., Sall, A., Touré, A. O., & Diop, S. (2022). Transfusion practice, post-transfusion complications and risk factors in sickle cell disease in Senegal, West Africa. Mediterranean Journal of Hematology and Infectious Diseases, 14(1), e2022004. https://doi.org/10.4084/MJHID.2022.004
Shih, A. W., Yan, M. T. S., Elahie, A. L., Barty, R. L., Liu, Y., Berardi, P., Azzam, M., Siddiqui, R., Parvizian, M. K., McDougall, T., Heddle, N. M., Al-Habsi, K. S., Goldman, M., Cote, J., Athale, U., & Verhovsek, M. M. (2020). Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to risk-stratify patients for alloimmunisation risk. Transfusion Medicine, 30(4), 263–274. https://doi.org/10.1111/tme.12685
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 Fazili, O. A., Mudogo, V., Ngbolua, K. T.